High-rolling investors have positioned themselves bearish on BioNTech BNTX, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in BNTX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 22 options trades for BioNTech. This is not a typical pattern.
The sentiment among these major traders is split, with 45% bullish and 54% bearish. Among all the options we identified, there was one put, amounting to $40,000, and 21 calls, totaling $854,477.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $95.0 for BioNTech over the last 3 months.
Volume & Open Interest Development
In today's trading context, the average open interest for options of BioNTech stands at 317.67, with a total volume reaching 4,596.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in BioNTech, situated within the strike price corridor from $70.0 to $95.0, throughout the last 30 days.
BioNTech Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| BNTX | CALL | SWEEP | NEUTRAL | 06/21/24 | $95.00 | $70.2K | 399 | 160 |
| BNTX | CALL | SWEEP | NEUTRAL | 06/21/24 | $95.00 | $62.5K | 399 | 267 |
| BNTX | CALL | TRADE | BULLISH | 01/17/25 | $95.00 | $50.8K | 321 | 320 |
| BNTX | CALL | TRADE | BEARISH | 01/17/25 | $95.00 | $47.1K | 321 | 227 |
| BNTX | CALL | SWEEP | BEARISH | 01/17/25 | $95.00 | $46.6K | 321 | 141 |
About BioNTech
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.
Having examined the options trading patterns of BioNTech, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Current Position of BioNTech
- Trading volume stands at 130,668, with BNTX's price down by -1.07%, positioned at $93.5.
- RSI indicators show the stock to be may be oversold.
- Earnings announcement expected in 52 days.
What Analysts Are Saying About BioNTech
In the last month, 1 experts released ratings on this stock with an average target price of $107.0.
- An analyst from HC Wainwright & Co. persists with their Buy rating on BioNTech, maintaining a target price of $107.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for BioNTech, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
